Literature DB >> 17313877

[A survey of medical therapies for chronic heart failure in primary hospitals in China].

Ya-min Cao1, Da-yi Hu, Hong-yu Wang, Yan Wu.   

Abstract

OBJECTIVE: To investigate the current medicine therapy of CHF in primary hospitals in China, and to propose the improvement ways.
METHODS: Physicians from 2066 primary hospitals in 17 areas of China completed investigating questionnaires about their medicine therapy of CHF. 2100 pieces of valid questionnaires were collected totally. Input all the data to computer 2 times and check up repeatedly till to be sure that there were no mistakes in the database, then to make statistics analysis by the SPSS soft kit.
RESULTS: The current medicine therapy of CHF in primary hospitals in China was not optimal: the use rate of large dosage digitalis (defined as oral digitalis > or = 0.25 mg/d) was 10 percent; the use rate of beta-blocker and ACEI (angiotensin-II converting enzyme inhibitors) was still low (40% and 80%, respectively); the use rate of the target dose of beta-blocker and ACEI were even lower (1% and 2%, respectively), in some underdeveloped areas they were zero; but in some developed areas the current medical therapy of CHF was better.
CONCLUSIONS: It is imperative to improve the current medicine therapy of CHF in primary hospitals in China. The first step might be to let more doctors who work in primary hospitals be familiar with "Guideline of CHF" and could practise it in clinic; the second one might be to open Out-patient Heart Failure Clinics in primary hospitals in order to that patients could be followed up regularly, so that to amend the current state.

Entities:  

Mesh:

Year:  2006        PMID: 17313877

Source DB:  PubMed          Journal:  Zhonghua Nei Ke Za Zhi        ISSN: 0578-1426


  5 in total

Review 1.  Heart failure in China: a review of the literature.

Authors:  Rinat Ariely; Keith Evans; Tim Mills
Journal:  Drugs       Date:  2013-05       Impact factor: 9.546

2.  Prognosis of patients with heart failure and reduced ejection fraction in China.

Authors:  Yu Xu; Yanan Shi; Zhongyu Zhu; Changhe Cui; Bei Li; Fang Chen; Dan Li; Songhu Chen; Yang Guo
Journal:  Exp Ther Med       Date:  2013-10-11       Impact factor: 2.447

3.  Digoxin is associated with worse outcomes in patients with heart failure with reduced ejection fraction.

Authors:  Jingmin Zhou; Juan Cao; Xuejuan Jin; Jun Zhou; Zhenyue Chen; Dingli Xu; Xinchun Yang; Wei Dong; Liwen Li; Yuyuan Fan; Li Chen; Qiaoqing Zhong; Micheal Fu; Kai Hu; Junbo Ge
Journal:  ESC Heart Fail       Date:  2020-01-29

4.  Problems with the outcome measures in randomized controlled trials of traditional Chinese medicine in treating chronic heart failure caused by coronary heart disease: a systematic review.

Authors:  Jiayuan Hu; Ruijin Qiu; Chengyu Li; Min Li; Qianqian Dai; Shiqi Chen; Chen Zhao; Hongcai Shang
Journal:  BMC Complement Med Ther       Date:  2021-08-31

5.  Care pathways and treatment patterns for patients with heart failure in China: results from a cross-sectional survey.

Authors:  James Ds Jackson; Sarah E Cotton; Sara Bruce Wirta; Catia C Proenca; Milun Zhang; Raquel Lahoz; Bogdan Balas; Frederico J Calado
Journal:  Drug Des Devel Ther       Date:  2018-07-26       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.